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Abstract
Anomalous methylation of tumor suppressor genes demands meticulous probing as it has been ﬁrmly
established as an important mechanism for gene inactivation. We examined a total of 50 epithelial ovarian
cancer (EOC) patients for hypermethylation of RASSF1A and PTEN genes in CpG islands located in the pro-
moter regions. Our data demonstrate that hypermethylation of RASSF1A might play a crucial role in the
prognosis of EOC.
Background: To investigate the methylation pattern in promoter region of RASSF1A and PTEN genes in epithelial
ovarian cancer patients in North India. Patients and Methods: Fifty patients and 20 healthy controls were studied.
Isolation of genomic DNA from peripheral blood and methylation-speciﬁc polymerase chain reaction (MSP) were
applied for analysis. Results: 17 of 50 patients (34.0%) were found to be methylated for RASSF1A gene, whereas
methylation of the PTEN gene occurred in 8 of 50 cases (16.0%). A statistically signiﬁcant result was obtained (P ¼ .01)
for RASSF1A gene and correlated with the patients’ clinicopathologic features. Conclusion: Hypermethylation of both
RASSF1A and PTEN genes in blood DNA from ovarian cancer patients might offer an exposition for early diagnosis of
the malignancy.
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Ovarian cancer is diagnosed in nearly a quarter of a million
women globally each year. It is the eighth most common cancer
in women and the seventh leading cause of cancer death among
women, responsible for approximately 140,000 deaths each year.
It has the highest mortality rate of all gynecologic cancers.1
Altered DNA methylation of tumor suppressor gene (TSG)
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http://dx.doi.org/10.1016/j.cogc.2014.12.002and frequently occurs as an early event in the development of
different types of cancers including ovarian carcinoma.2 TSGs
RASSF1A and PTEN were analyzed in this study to evaluate the
role of promoter hypermethylation in epigenetic silencing of the
genes leading to the malignant transformation of the ovary. DNA
methylation is one of the epigenetic mechanisms that plays a role
in many important biological processes including X-inactivation,
silencing parasitic DNA elements, genomic imprinting, aging,
male infertility, and cancer.3-9 Aberrant DNA methylation at
CpG islands, often in close proximity to transcription start sites, is
associated with the epigenetic regulation of genes through altered
transcription factor binding and chromatin structure.10 Results
have shown that CpG islands display tumor-speciﬁc patterns of
aberrant methylation,11 whereas selected CpG islands have been
reported to show stage-speciﬁc patterns of aberrant methyl-
ation.12-16 RASSF1A gene encodes a protein similar to the Rat
Sarcoma effecter proteins. Loss or altered expression of this gene
has been associated with the pathogenesis of a variety of cancers,
which suggests the tumor suppressor function of this gene. TheClinical Ovarian and Other Gynecologic Cancer December 2014 - 33
Table 1 Primer Sequence for Methylation-Speciﬁc Polymerase Chain Reaction Used for RASSF1A and PTEN Genes





RASSF1A unmethylated GGAGGATAGTTGGATTGAGTTAATGTT GGTTTTTGTGAGTGTGTTTAG 60 169
RASSF1A methylated GCTAACAAACGCGAACCG CCCTCCCAAACGCCGA 60 169
PTEN unmethylated TGGGTTTTGGAGGTTGTTGGT ACTTAACTCTAAACCACAACC 61 155
PTEN methylated GGTTTCGGAGGTCGTCGGC CAACCGAATATTAACTACTACGACG 61 155
Hypermethylation of RASSF1 and PTEN
34 -inactivation of this gene was found to be correlated with the
hypermethylation of its CpG-island promoter region. Similarly,
the TSG, PTEN, has previously been demonstrated to be involved
in tumorigenesis and tumor progression. The aim of the present
study was to investigate the methylation status and signiﬁcance of
RASSF1A and PTEN genes in ovarian carcinoma and to deter-
mine the association between RASSF1A and PTEN gene promoter
methylation with clinicopathologic features.
Materials and Methods
Study Population
The study was conducted in Cancer Genetics Lab, Department
of Biochemistry, Maulana Azad Medical College and Department of
Obstetrics and Gynecology, Lok Nayak Hospital, New Delhi. It
was a hospital-based caseecontrol study. A total of 50 epithelial
ovarian cancer (EOC) patients and 20 age-matched healthy female
volunteers were included in the study. EOC patients were assessed
on the basis of clinical and pathologic parameters. Diagnosis of all
tumors was veriﬁed by 2 senior pathologists. The cancer was staged
according to the International Federation of Gynecology and Ob-
stetrics (FIGO) surgical staging system. Informed consent form was
signed by all patients, and research protocol was approved by the
institutional ethical committee.
Selection Criteria of Patients
Inclusion Criteria. This study included newly diagnosed, un-
treated cases of histopathologically conﬁrmed EOC patients with
normal, elevated, or depressed values of CA125.
Exclusion Criteria. Patients with a history of previous cancer or
metastasized cancer from any other organ were not included in this
study.Figure 1 Gel Electrophoresis Band Pattern for RASSF1A Gene Meth
Transillumination Yielding 169-bp Polymerase Chain Reac
Abbreviations: L ¼ lane; M ¼ methylated; U ¼ unmethylated.
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3 millilitres of peripheral blood was collected after conﬁrmed
diagnosis in EDTA vials. Blood samples were also collected from 20
age-matched, cancer-free female volunteers as controls.
The study included 50 untreated patients who were newly
diagnosed for epithelial ovarian malignancy at the Department
of Pathology, Maulana Azad Medical College and Associated
Hospitals, New Delhi, between June 2012 and December 2013.
Patients were either in the reproductive, premenopausal, or
postmenopausal phase. Information about family, general, gyneco-
logic, and obstetric history, indication for surgery, other relevant
diseases, and current therapy plan were collected. The purpose of
the sampling was explained to all patients, and written informed
consent was obtained before enrollment. The study was approved
by the Institutional Ethics Committee of Maulana Azad Medical
College.
DNA Extraction
DNA from peripheral blood samples was extracted using
Genomic DNA Mini Kit (GeneAid) according to the manufac-
turer’s instructions and stored at 4C. The quality and integrity of
the DNA was determined by the A260/280 ratios. DNA quality was
also checked by ethidium bromide staining on 1% agarose gel under
ultraviolet (UV) transillumination.
Bisulphite Modiﬁcation of Genomic DNA. Genomic DNA was
modiﬁed with Sodium bisulphite using BisulFlash DNA Modiﬁ-
cation Kit (Epigentek, Farmingdale, NY). Starting DNA ranged
from 50 to 200 ng per reaction. Bisulphite conversion of DNA was
carried out at 95C for 20 minutes during which unmethylated
cytosine was converted into uracil completely. This was followed by
the converted DNA clean up and storage at 80C before use.ylation Visualized Under 3% Agarose Gel Under Ultraviolet
tion Product
Figure 2 Gel Electrophoresis Band Pattern for RASSF1A Gene Methylation Visualized Under 3% Agarose Gel Under Ultraviolet
Transillumination Yielding 155-bp Polymerase Chain Reaction Product
Abbreviations: L ¼ lane; M ¼ methylated; U ¼ unmethylated.
Table 2 Clinicopathologic Proﬁles of the Epithelial Ovarian
Cancer Cases in the Study













Clear cell 1 02.0
Endometroid 2 04.0
Undifferentiated 2 04.0
Mariyam Zuberi et alMethylation-Speciﬁc Polymerase Chain Reaction (MSP)
Bisulphite-treated DNA was used for methylation-speciﬁc PCR
using primer sets as shown (Table 1) to distinguish between
methylated (M) and unmethylated (U) DNA. PCR was performed
in a total volume of 25 mL, using the DreamTaq Master Mix
(Fermentas), converted DNA 0.3 ml each of 25 pm of oligonucle-
otides and programmed at 94C for 45 seconds, 60C (for
RASSF1A) or 61C (for PTEN) for 50 seconds, and 72C for 45
seconds for 40 consecutive cycles. 10ml of each PCR reaction was
directly loaded onto a 3% agarose gel, stained with ethidium bro-
mide, and visualized under UV illumination. A band size of 169 bp
was observed in the RASSF1A methylation set (Figure 1), whereas a
band size of 155 bp in the PTEN methylated set (Figure 2).
Statistical Analysis
The data analysis was performed using the SPSS 16.0 (SPSS for
Windows, Chicago) software package. The association between
hypermethylation of RASSF1A and PTEN genes with clinicopath-
ologic parameters was statistically analyzed using the chi-square and
Fisher exact test. A P value of .05 was considered statistically
signiﬁcant.
Patient Characteristics
Clinicopathologic features including the age, menopausal status,
stage, and histopathology are provided in Table 2. To elucidate the
effect of promoter hypermethylation of RASSF1A and PTEN genes
on the onset of cancer, EOC patients were divided into 2 groups,
 40years(50%) and > 40 years (50%). Cases were divided ac-
cording to the FIGO staging of EOC and histopathologic types. In
this study, greatest number of cases were in advanced stage (80%)
compared with early stage. According to histopathologic type,
greatest number of cases were in serous adenocarcinoma (46%),
then mucinous adenocarcinoma (44%), endometroid and undif-
ferentiated carcinoma (4%), and clear cell carcinoma (2%). No
patient had a family history of EOC.
Results
Distribution of Methylation of RASSF1A and PTEN
Genes Among Cases and Controls
Table 3 depicts the allocation of methylation frequencies of the
RASSF1A and PTEN genes in cases and controls. There was asigniﬁcant difference (P ¼ .01) observed with RASSF1A gene,
whereas PTEN gene yielded nonsigniﬁcant results when compared
with that of healthy female controls. The result shows that
methylation of RASSF1A is more frequent (34.0%) in cases as
against those in controls (5.0%). On the other hand, methylation of
PTEN gene was found to be less frequent (16.0%) when matched
with the frequency in controls (84.0%).Our results indicate that
patients who show hypermethylation of the RASSF1A gene have a
signiﬁcantly increased risk of developing EOC and can be a useful
marker in studying the prognosis of the disease.
Association of RASSF1A and PTEN Gene Promoter
Hypermethylation With Age at Diagnosis
Table 4 describes the association of RASSF1A and PTEN gene
promoter hypermethylation and its association with age at diagnosis.
In both groups 40 and> 40 years, the association was found to be
nonsigniﬁcant (0.5 and 0.3, respectively) although RASSF1A gene
hypermethylation was found to be more evident (44.0%) in the age
group > 40 years compared with the age group  40 years (24.0%).Clinical Ovarian and Other Gynecologic Cancer December 2014 - 35





Samples, n (%) Chi-Square df P Value
RASSF1A, cases 17 (34.0) 33 (66.0) 4.86 1 .01
RASSF1A, controls 1 (5.0) 19 (95.0)
PTEN, cases 8 (16.0) 42 (84.0) 0.07 1 .09
PTEN, controls 0 (0.0) 20 (100.0)
Abbreviation: df ¼ degree of freedom.
Hypermethylation of RASSF1 and PTEN
36 -Association of RASSF1A and PTEN Gene Promoter
Hypermethylation With Menopausal Status
A signiﬁcant correlation (P ¼ .003) was found between the
RASSF1A gene hypermethylation and the menopausal status.
RASSF1A gene aberrant methylation was more frequent in the
postmenopausal women (62.5%) as against the reproductive age-
group women (20.5%).Whereas, no association was seen in the
PTEN gene aberrant hypermethylation and the menopausal status.
Association of RASSF1A and PTEN Gene Promoter
Hypermethylation With Stage of the Disease
There was no correlation established between RASSF1A and
PTEN gene promoter hypermethylation with stage of the disease
although an increased percentage in the advanced stage disease can
be observed (37.5% and 20.0%, respectively).
Association of RASSF1A and PTEN Gene Promoter
Hypermethylation With Different Histologic Types
A signiﬁcant association (P ¼ .03) was found between the
methylation status of RASSF1A gene with different histologic types.
Serous adenocarcinoma was found to be the highest (56.5%)
compared with mucinous, clear cell, endometroid, and undifferen-
tiated epithelial ovarian adenocarcinoma.
Discussion
TSGs play crucial roles in several aspects of cancer development
including cell cycle control, signal transduction, angiogenesis,







Age(years) 40 6 24.0
>40 11 44.0
Menopausal status Pre 7 20.5
Post 10 62.5
Stage Early 2 20.0
Advanced 15 37.5
Histopathology Mucinous 4 18.1
Serous 13 56.5
Clear cell 0 0.0
Endometroid 0 0.0
Undifferentiated 0 0.0
Clinical Ovarian and Other Gynecologic Cancer December 2014a broad array of normal and tumor-related functions. It is proposed
that TSGs provide a vast untapped resource for anticancer ther-
apy.17 It has been reported that TSGs contribute to ovarian cancer
development through DNA damage, DNA repair, regulating
macromolecule metabolism, cell cycle, and apoptosis.18
In this study, we conducted an analysis of RASSF1A and PTEN
methylation status to deﬁne its putative role as a possible tumor-
speciﬁc and transcription regulatory event occurring in EOC.
In addition to changes in DNA and chromosomes, it has
become evident that oncogenomic processes can be profoundly
inﬂuenced by epigenetic mechanisms. DNA methylation is one of
the key epigenetic factors involved in regulation of gene expression
and genomic stability and is biologically necessary for the main-
tenance of many cellular functions. Although there has been
considerable progress in understanding the impact of genetic and
epigenetic mechanisms in tumor genesis, there has been little
consideration of the importance of the interplay between these 2
processes.
Most recent studies have focused on the study of epigenetic
changes resulting in many types of cancers. DNA methylation was
the ﬁrst epigenetic alteration to be observed in cancer cells. DNA
methylation involves addition of a methyl group to the carbon-5
position of the cytosine ring. This reaction is catalyzed by DNA
methyltransferase in the context of the sequence 5’-CG-3’, which is
also referred to as a CpG dinucleotide.19,20 The methylation of
gene, particularly the methylation of CpG-rich promoters, could
block transcriptional activation. The potential contribution of DNA
methylation to oncogenesis is mediated by 1 or more mechanismsion With the Clinicopathologic Features of Epithelial Ovarian
P Value
PTEN
Methylation Methylation (%) P Value
.2 5 20.0 .6
3 12.0
.009 6 17.6 1
2 12.5
.5 0 0.0 .1
8 20.0





Figure 3 Distribution of RASSF1A Methylation in Various Cancers All Over the World
Abbreviations: NSCLC ¼ nonesmall cell lung cancer.
Mariyam Zuberi et althat include DNA hypomethylation, hypermethylation of TSG, and
chromosomal instability in cancers.20-27
In the present study, we used MSP for analysis of the methylation
status of RASSF1A and PTEN gene. This method provided signif-
icant advantages over previous ones used for assaying methylation.
MSP is much more sensitive than Southern blot analysis, facilitating
the detection of low numbers of methylated alleles and the study of
DNA from small samples. MSP allows examination of all CpG sites,
not just those within sequences recognized by methylation-sensitive
restriction enzymes.
RASSF1A promoter methylation was detected in 34% in EOC
patients. PTEN methylation was seen in 16% of patients only
signifying a very less percentage of patients, which was
nonsigniﬁcant.
RASSF1A promoter hypermethylation has been observed in a
variety of human cancers such as pancreatic endocrine tumor,28
colorectal cancer,29 nasopharyngeal carcinoma,30 prostate cancer,31Figure 4 Distribution of PTEN Methylation in Various Cancers All Oovary and renal,32 hepatocellular carcinoma,33 breast cancer,34
nonesmall cell lung cancer,35 and gastric cancer36 as depicted in
Figure 3.
PTEN aberrant promoter methylation was detected in breast
cancer patients,37 melanoma,38 sporadic colorectal cancer,39 gastric
cancer,40 oral cancer,41 and endometrial cancer.42 No PTEN pro-
moter methylation was found in ovarian adenocarcinoma
(Figure 4).43
In the present study, RASSF1A and PTEN methylation was
found in a frequency as high as 34% and 16%, respectively, with a
signiﬁcant P value (.01) for RASSF1A gene. Table 5 provides the
percentage of methylation in RASSF1A gene, PTEN gene, both
RASSF1A and PTEN genes, and no methylation. Methylation was
detected in 34% patients for the RASSF1A gene and 16% in
patients for PTEN gene, whereas no methylation was established in
healthy controls for PTEN gene. Also RASSF1A aberrant promoter
methylation was found to be signiﬁcantly associated between serousver the World
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Table 5 Percentage of RASSF1A and PTEN Gene Methylation
in Epithelial Ovarian Cancer Patients
Gene Methylation
Number of
Patients (n) Percentage (%)
RASSF1A methylation 17/50 34.0




No methylation 30/50 68.0
Hypermethylation of RASSF1 and PTEN
38 -and mucinous histologic types (P ¼ .03). However, there was no
correlation found between RASSF1A aberrant promoter methyl-
ation and other demographic clinicopathologic factors such as age,
stage, CA 125, and so forth. Also, no correlation was seen between
PTEN methylation and various clinicopathologic factors including
age, menopause, stage histology, and CA 125.
Conclusion
Our data suggest that RASSF1A is a target for inactivation by
promoter methylation and may play an important role in prognosis
of EOC patients.
RASSF1A promoter methylation is associated with stage of EOC
and was found higher in advanced-phase than in early-phase
patients, but data did not reach to a statistically signiﬁcant value
because of limited number of EOC patients. RASSF1A promoter
methylation was found to be signiﬁcantly higher in post menopausal
cases than in premenopausal EOC patients.
PTEN promoter methylation is not associated with clinical
parameters of ovarian cancer patients.
Clinical Practice Points
What Is Already Known About This Subject?
 DNA hypermethylation has been extensively studied as an
epigenetic modiﬁcation in humans and has been linked to cancer
since a long time.
 Typically, it guarantees appropriate regulation of gene expres-
sion, but when there is an excessive increase in the methylation
pattern of DNA residues, it gives rise to tumorigenesis because it
leads to inactivation of certain tumor suppressor genes (TSGs)
within the promoter regions.
 There are scores of studies that have shown a broad range of
genes silenced by DNA methylation in different cancer types.What Are the New Findings?
 Further exploration is still needed as epigenetics pose a
challenge in inﬂicting tremendous harm. Moreover, it has
recently been speculated that DNA methylation can be used
to accurately predict age of a broad spectrum of tissues and
cell types.
 Our results indicate that the hypermethylation of TSG RASSF1A
might play a pivotal role in predicting the phenotype of epithelial
ovarian cancer (EOC) and its prognosis. The hypermethylation
of PTEN gene however does not offer much in anticipation to
the outcome of this disease.Clinical Ovarian and Other Gynecologic Cancer December 2014How Might It Impact on Clinical Practice in the Foreseeable
Future?
 It can be postulated that studying hypermethylation of TSGs
might offer a promising future in the early diagnosis of EOC
patients which is the need of the hour.
 Also, it might furnish a robust way out in analyzing the pro-
gression of the disease following its prognosis.Acknowledgments
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